Ampio Pharma: Up after COVID-19 drug study advances to full enrollment

Ampio Pharmaceuticals

02/12/2020 15:35

** Drug developer's shares  AMPE.A  rise 4.5% to $0.96
    ** AMPE says an early-stage trial testing its lead drug
candidate, Ampion, in the treatment of COVID-19 patients can
proceed to complete enrollment of the remaining patients
 urn:newsml:reuters.com:*:nPn4TP6Dya
    ** Says this follows clearance by an independent safety
monitoring panel that found Ampion to be safe and well-tolerated
    ** The trial will enroll 40 patients; 34 patients remaining
to be enrolled - co
    ** Co says Ampion is administered by inhalation in the
trial, allowing the drug to directly target and reduce
inflammation in the lungs; main goal is safety of drug
    ** Up to Tuesday's close, stock up 56.8% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))